Furthermore, Liang et al. recently reported that combinations of clinically approved mTOR inhibitors and chemotherapeutics synergized in inhibiting cell proliferation of KRAS mutant NSCLC cells in vitro and in vivo, and the efficacy of this approach correlated with the magnitude of mTOR activity induced by chemotherapy alone [123]. This evidence concerns the gene KRAS and non-small cell lung carcinoma.